Press Releases

Name: Medicure Inc.
Address: 1250 Waverley Street, Winnipeg, Manitoba, R3T 6C6
Price range: $$

Medicure Announces Normal Course Issuer Bid May 17, 2018	Medicure Reports Financial Results for Quarter and Year Ended December 31, 2017 May 1, 2018	Medicure announces availability of ZYPITAMAG™ (pitavastatin) in the U.S. May 1, 2018
Medicure to Announce Fiscal Year End 2017 Financial Results on April 30, 2018 April 24, 2018	Medicure Announces Further Up-Date on PREXXARTAN® March 28, 2018	Medicure Announces an Up-Date on PREXXARTAN® Launch March 19, 2018
Zydus partners with Medicure to launch its NDA Product, ZYPITAMAG (pitavastatin) in the U.S. March 7, 2018	Medicure Announces Receipt of Deferred Proceeds from Apicore Sale February 1, 2018	Medicure Announces FDA Approval Received for Prexxartan® December 17, 2017
Medicure Acquires Exclusive License to Sell and Market Branded Cardiovascular Drug in the U.S. December 14, 2017	Medicure Reports Financial Results for Quarter Ended September 30, 2017 November 21, 2017	Medicure Announces Repayment of Outstanding Debt November 17, 2017
Medicure Q3 Results and Conference Call Dates November 15, 2017	Medicure Acquires Exclusive License to Sell and Market PREXXARTAN® in the U.S. from Carmel Biosciences October 31, 2017	Medicure Announces Sale of Apicore Business October 3, 2017
Medicure Reports Financial Results for Quarter Ended June 30, 2017 August 7, 2017	Medicure Q2 Results and Conference Call Dates August 2, 2017	Medicure Closes Acquisition of Additional Interests in Apicore July 12, 2017
Medicure Exercises Option to Acquire Additional Interests in Apicore July 10, 2017	Medicure Provides Update on Apicore Purchase Option July 3, 2017	Medicure Reports Financial Results for Quarter Ended March 31, 2017 May 24, 2017
Medicure Q1 Results and Conference Call Dates May 18, 2017	Medicure Reports Financial Results for Quarter and Year Ended December 31, 2016 April 26, 2017	Medicure to Announce Fiscal Year End 2016 Financial Results on April 26, 2017 March 29, 2017
Medicure Announces FDA Approval for Apicore's Generic Tetrabenazine March 23, 2017	Medicure Provides Apicore Secured Loan to Replace Knight Loan January 9, 2017	Medicure announces filing of ANDA in collaboration with Apicore December 13, 2016
Medicure Closes Acquisition of Majority Interest in Apicore December 1, 2016	Medicure to Hold Investor Call on November 21, 2016 November 18, 2016	Medicure Exercises Option to Acquire Majority Interest in Apicore November 18, 2016
Medicure Reports Third Quarter 2016 Financial Results November 9, 2016	Medicure to Announce Q3 2016 Financial Results on November 9, 2016 November 2, 2016	FDA Approves New AGGRASTAT® Product Format September 1, 2016
Medicure Reports Second Quarter 2016 Financial Results August 10, 2016	Medicure to Announce Q2 2016 Financial Results on August 10, 2016 August 3, 2016	Medicure Receives Response Letter from FDA on AGGRASTAT® sNDA for New Indication July 7, 2016
Medicure Reports First Quarter 2016 Financial Results May 11, 2016	Medicure Files Application for New AGGRASTAT® Product Format May 11, 2016	Medicure Announces Departure of President and Chief Operating Officer May 9, 2016
Medicure to Announce Q1 2016 Financial Results on May 11, 2016 May 4, 2016	Medicure Announces Grant of Options April 7, 2016	Medicure Announces Upcoming Conference Presentations April 5, 2016
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2015 March 30, 2016	Medicure To Announce Fiscal Year 2015 Financial Results on March 30, 2016 March 23, 2016	Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference February 23, 2016
Medicure to present at Cantech Investment Conference January 21, 2016	Medicure Announces Preliminary Revenue For Fiscal 2015 January 11, 2016	Medicure announces ANDA collaboration with Apicore January 6, 2016
Medicure Announces PDUFA Action Date for New Aggrastat Indication December 2, 2015	Medicure Announces Grant of Stock Options November 25, 2015	Medicure Reports Third Quarter 2015 Financial Results November 9, 2015
Medicure Q3 Results and Conference Call Dates November 3, 2015	Medicure Announces Filing of sNDA for New AGGRASTAT® Indication September 10, 2015	Medicure Reports Second Quarter 2015 Financial Results August 11, 2015
Medicure Q2 Results And Conference Call Dates August 5, 2015	Medicure Announces Grant Of Options July 7, 2015	Medicure Closes Bought Deal Private Placement Financing for Gross Proceeds of $4,025,000 June 26, 2015
Medicure Announces $3.5 Million "Bought Deal" Private Placement June 10, 2015	Medicure Reports Financial Results for the First Quarter of 2015 April 29, 2015	Medicure Q1 Results and Conference Call Dates April 27, 2015

Newer | Older

Press Releases

Medicure Announces Normal Course Issuer Bid

Medicure Reports Financial Results for Quarter and Year Ended December 31, 2017

Medicure announces availability of ZYPITAMAG™ (pitavastatin) in the U.S.

Medicure to Announce Fiscal Year End 2017 Financial Results on April 30, 2018

Medicure Announces Further Up-Date on PREXXARTAN®

Medicure Announces an Up-Date on PREXXARTAN® Launch

Zydus partners with Medicure to launch its NDA Product, ZYPITAMAG (pitavastatin) in the U.S.

Medicure Announces Receipt of Deferred Proceeds from Apicore Sale

Medicure Announces FDA Approval Received for Prexxartan®

Medicure Acquires Exclusive License to Sell and Market Branded Cardiovascular Drug in the U.S.

Medicure Reports Financial Results for Quarter Ended September 30, 2017

Medicure Announces Repayment of Outstanding Debt

Medicure Q3 Results and Conference Call Dates

Medicure Acquires Exclusive License to Sell and Market PREXXARTAN® in the U.S. from Carmel Biosciences

Medicure Announces Sale of Apicore Business

Medicure Reports Financial Results for Quarter Ended June 30, 2017

Medicure Q2 Results and Conference Call Dates

Medicure Closes Acquisition of Additional Interests in Apicore

Medicure Exercises Option to Acquire Additional Interests in Apicore

Medicure Provides Update on Apicore Purchase Option

Medicure Reports Financial Results for Quarter Ended March 31, 2017

Medicure Q1 Results and Conference Call Dates

Medicure Reports Financial Results for Quarter and Year Ended December 31, 2016

Medicure to Announce Fiscal Year End 2016 Financial Results on April 26, 2017

Medicure Announces FDA Approval for Apicore's Generic Tetrabenazine

Medicure Provides Apicore Secured Loan to Replace Knight Loan

Medicure announces filing of ANDA in collaboration with Apicore

Medicure Closes Acquisition of Majority Interest in Apicore

Medicure to Hold Investor Call on November 21, 2016

Medicure Exercises Option to Acquire Majority Interest in Apicore

Medicure Reports Third Quarter 2016 Financial Results

Medicure to Announce Q3 2016 Financial Results on November 9, 2016

FDA Approves New AGGRASTAT® Product Format

Medicure Reports Second Quarter 2016 Financial Results

Medicure to Announce Q2 2016 Financial Results on August 10, 2016

Medicure Receives Response Letter from FDA on AGGRASTAT® sNDA for New Indication

Medicure Reports First Quarter 2016 Financial Results

Medicure Files Application for New AGGRASTAT® Product Format

Medicure Announces Departure of President and Chief Operating Officer

Medicure to Announce Q1 2016 Financial Results on May 11, 2016

Medicure Announces Grant of Options

Medicure Announces Upcoming Conference Presentations

Medicure Reports Financial Results for Quarter and Year Ended December 31, 2015

Medicure To Announce Fiscal Year 2015 Financial Results on March 30, 2016

Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference

Medicure to present at Cantech Investment Conference

Medicure Announces Preliminary Revenue For Fiscal 2015

Medicure announces ANDA collaboration with Apicore

Medicure Announces PDUFA Action Date for New Aggrastat Indication

Medicure Announces Grant of Stock Options

Medicure Reports Third Quarter 2015 Financial Results

Medicure Q3 Results and Conference Call Dates

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

Medicure Reports Second Quarter 2015 Financial Results

Medicure Q2 Results And Conference Call Dates

Medicure Announces Grant Of Options

Medicure Closes Bought Deal Private Placement Financing for Gross Proceeds of $4,025,000

Medicure Announces $3.5 Million "Bought Deal" Private Placement

Medicure Reports Financial Results for the First Quarter of 2015

Medicure Q1 Results and Conference Call Dates

Stay Connected

Sign up for our newsletter

About

MC-1 for PNPO Deficiency

Products

Online Pharmacy

Newsroom

Investors